ANTIMICROBIAL AGENTS ANDCHEMOTHERAPYVOLUME 1 * NUMBER 6 * JUNE 1972

EDITORIAL BOARD

GLADYS L. HOBBY, Editor-in-Chief (1975)Infectious Disease Research Institute, East Orange, N.J.

WALTER D. CELMER, Editor (1975)Pfizer hIc., Grotoln, Coiml.

JOEL G. FLAKS, Editor (1976)University ofPennsylvania, Phliladelphia

EDWARD W. HOOK, Editor (1976)University of Virginia, Charlottesville

LEON H. SCHMIDT, Editor (1974)Southern Research Institute, Birminglham, Ala.

Fred Allison, Jr. (1973)Theodore Anderson (1973)Robert Austrian (1974)John Bennett (1973)Joe Bertino (1974)E. Borowski (1973)D. Buyske (1974)Yves Chabbert (1974)Patricia Charache (1974)Ernest Chick (1973)Leighton E. Cluff (1974)Frank Collins (1973)John Corcoran (1974)Julian Davies (1973)Bernard Davis (1973)Arnold L. Demain (1973)Roger DesPrez (1973)Liebor Ebringer (1974)H. L. Ennis (1974)Maxwell Finland (1973)Harry Gooder (1973)M. Gorman (1974)

H. Grisebach (1974)Jack Gwaltney (1974)Fred Hahn (1973)William Hewitt (1974)Richard Hornick (1974)Milton Huppert (1974)George Gee Jackson (1974)Keith Jensen (1974)E. H. Kass (1973)Donald Kaye (1973)WVm. Kirby (1973)Vernon Knight (1974)M. Glenn Koenig (1973)Calvin Kunin (1972)Mark Lepper (1972)Robert G. Loudon (1974)Thomas H. Maran (1974)Lester Mitscher (1974)S. Mitsuhashi (1974)R. B. Morin (1973)L. Nickell (1974)David Perlman (1972)

T. J. Perun (1974)K. E. Price (1973)C. Reilly (1972)R. W. Rickards (1974)R. W. Riddell (1974)Richard Roberts (1973)L. Sabath (1973)Arthur K. Saz (1973)F. C. Sciavolino (1973)Piero Sensi (1974)David Smith (1974)Earle Spaulding (1974)Gene Stollerman (1974)R. Sutherland (1973)Morton N. Swartz (1973)Ralph Tompsett (1973)John P. Utz (1973)D. Vazquez (1974)G. H. Wagman (1974)Kenneth S. W'arren (1973)B. Weisblum (1973)Temple Williams (1973)

ROBERT A. DAY, Managing Editor, 1913 1 St., N. W., Washingtont, D.C. 20006

EX OFFICIOMORRIS F. SHAFFER, President (1971-1972) R. G. E. MURRAY, Vice-President (1971-1972)

DONALD E. SHAY, Secretary

Antimicrobial Agents and Chemotherapr, a publication of theAmerican Society for Microbiology, 1913 I St., N.W., Washington,D.C. 20006, is devoted to the dissemination of knowledge relatingto all aspects of antimicrobial agents and chemotherapy, includingcancer chemotherapy. Antimicrobial Agents and Clhemotherapyis published monthly, and the twelve numbers are divided intotwo volumes per year. The subscription price is $40 (foreign, $41)per year. Single copies are $4.00 (foreign, $4.25). Members of theAmerican Society for Microbiology may receive AntimicrobialAgents and Chemotherapy as part of their dues. Correspondencerelating to subscriptions, reprints, defective copies, availability ofback issues, lost or late proofs, disposition of submitted manu-

scripts, and general editorial matters should be directed to theASM Publications Office, 1913 I St., N.W., Washington, D.C.

T. J. CARSKI, Treasurer

20006. Correspondence from ASM members relating to member-ship dues, member subscriptions, changes of address, incorrectjournaLs, etc, should be directed to the Executive Secretary,American Society for Microbiology, 1913 I St., N.W., Washington,D.C. 20006. Published monthly by the ASM at 428 E. Preston St..Baltimore, Md 21202.

Application to mail at second-class postage rates is pending atWashington, D.C.Made in the United States of America.Copyright © 1972, American Society for MicrobiologyAll Rights Reserved.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

INSTRUCTIONS TO AUTHORSSubmit manuscripts in duplicate (original and one

carbon) to ASM Publications Office, 1913 I St., N.W.,Washington, D.C. 20006.

General policy. Any manuscript submitted must bea report of unpublished original research, which is notbeing considered for publication elsewhere. Eachmanuscript should present the results of an independ-ent, cohesive study; "series" papers are discouraged.A manuscript accepted and published by this journalmust not be published again in any form without theconsent of ASM.A charge of $25 per printed page is assessed for

publication. Most institutions and granting agenciesin the United States permit the payment of publicationcharges as a part of their general research support. Itis recognized, however, that such funds are not alwaysavailable to laboratories outside the United States.In such cases, the cost of publication will be borne bythe American Society for Microbiology.The "editorial style" of this journal essentially fol-

lows the Style Manualfor Biological Journals (2nd ed.,AIBS, 1964). Genetics symbols should essentially fol-low the recommendations of Demerec et al. (Genetics54:61, 1966) as updated and used by Taylor (Bacteriol.Rev. 34:155, 1970) and Sanderson (Bacteriol. Rev.34:176, 1970). The standard italicized, lower-case,three-letter symbol should be used for genotypelesignation, and care should be taken to avoid using;his symbol for the designation of phenotype. Theatter can be abbreviated in one form or another, but;hould be stated in words at first use in the text.3iochemical abbreviations and nomenclature shouldssentially follow "Biochemical Nomenclature" inr9Iandbook of Biochemistry (2nd ed., 1970. H. A.ober, ed. The Chemical Rubber Co., Cleveland, p.k4-A24). Normally, abbreviations (except those oftandard units of measurement and symbols of thelements) should be defined and introduced paren-hetically at first use in the text. Enzyme activity should)e expressed in terms of international units (EnzymeVomenclature, Elsevier Publishing Co., 1965), and theEC number should be given parenthetically at firstise in the text. In expressing lengths, weights, and'olumes, the prefixes nano (n) and pico (p) should beised instead of millimicro (m,) and micromicro (jAp)._xpress lengths in nanometers (nm; 10- m) or innicrometers (jim; 10-6 m) instead of millimicrons (m,u;.09 m), microns (jA: 10-6 m), or Angstroms (A; 10-10n). Express parts per million (ppm) as micrograms)er milliliter (ug/ml), micrograms per gram (,ug/g), ornicroliters per liter (,uliters/liter), as appropriate. In,eneral, measurements should be expressed in terms oftandard international metric units. The journal re-erves the privilege of editing manuscripts to makehem conform with the adopted style.Form of manuscript. All parts of the manuscript

,hould be typed double-space or, preferably, triple-pace. Most manuscripts can and should be dividednto the following sections: Abstract, Introduction,wAaterials and Methods, Results, Discussion, Ac-cnowledgments, and Literature Cited.Abstract. An Abstract appears at the beginning of

ach paper. The Abstract should not exceed 250 words.Literature Cited. In the text, references are cited by

iumber. The Literature Cited section should be typedn alphabetical order, by first author, and numbered.4ames ofjournals are abbreviated according to Access

(American Chemical Society, 1969). Citations of ab-stracts, theses, "unpublished data," "personal com-munication," and "in press" will not be accepted inthe Literature Cited.

Tables. Each table should be typed on a separatepage. The data should be arranged so that columns oflike material read down, not across. The headingsshould be sufficiently clear so that the meaning of thedata will be understandable without reference to thetext. Explanatory footnotes are permitted, but detaileddescriptions of the experiments are not. The materialsand methods used to gain the data should properlyremain in the section of that name.

Figures. A complete set of figures, preferably glossyphotographs, should accompany each of the twocopies of the manuscript. Each figure should be num-bered and should include the name of the authoreither in the margin or on the back (marked lightlywith a soft pencil). Graphs (submit as photographs)should be finished drawings not needing further art-work or type-setting. Absolutely no part of a graphshould be typewritten (except the legend, which shouldbe typed on a separate page). All lettering should bedone with a lettering set. Most graphs will be reducedto one-column width, and all elements in the drawingshould be prepared to withstand this reduction. Thelegend of the figure should provide enough informa-tion so that the figure is understandable withoutreference to the text. Experimental details from Mate-rials and Methods should not be repeated in figurelegends.Nomenclature of microorganlisms. The name of a

species is a binary combination consisting of the nameof the genus followed by a specific epithet. In general,the nomenclature presented in Bergey's Manual ofDeterninative Bacteriology (7th ed., 1957) is used. Ifan author challenges this nomenclature, his own judg-ment will be followed, but the name in Bergey'sManual should follow in parentheses the first time thename is used in the text and in the Abstract. When anew bacterial name is proposed in a manuscript, aninternational authority on nomenclature will beconsulted for an opinion. When a new species, or anew variety of a species, is proposed, an acceptablephotomicrograph or electron micrograph of the cellsshould be submitted. If the cells are motile, the photo-micrograph or electron micrograph should show thenature and arrangement of flagella. As one of therequirements for description of a new species, werequire deposition of the type culture in a recognizedculture collection and designation of the accessionnumber.

Notes. The accepted form for Notes is somewhatdifferent from the foregoing. Contributors should con-sult a recent issue for style. Notes should not exceed500 words. The Abstract should not exceed 25 words.

Copyright. Once a paper has been published in thisjournal, which is a copyrighted publication, the legalownership of all parts of the paper, including the illus-trations, has passed from the author to the ASM. Ifthe same author, or any author, wishes to republishmaterial previously published in this journal, he mustfirst receive written permission from ASM.

Reprints. Reprints (in multiples of 100) may be pur-chased by contributors. A table showing the cost ofreprints, and an order form, will be sent with theproof.

AUTHOR INDEX

VOLUME 1

Ablashi, D. V., 82Abramson, I. J., 451Adamson, R. H., 82Akerkar, A. S., 392Aoki, H., 192Armstrong, Ellmore, N. W., 82Asher, Yael, 171, 483

Ball, Robert J., 80Barza, Michael, 268, 427Bayne, H. G., 263Bear, D., 303Beaty, Harry N., 397Becker, Yechiel, 171, 483Bennett, John E., 476Bergeron, Michel G., 280Berman, Harris A., 268Berman, S., 303Block, Edward R., 476Bodey, Gerald P., 343, 348, 358Borders, D. B., 403Bradley, S. G., 489Bran, Jose L., 35, 174, 235Brannon, D. R., 237, 242, 247Brenner, V. C., 116Brusch, John L., 280Bryan, L. E., 22Buck, R. E., 67Burrous, S. E., 85

Came, Paul E., 143Carlisle, Harold N., 460Case, C., 263Chen, Chi-Pien, 159Cheng, K. -J. Cheng, 447Chow, Anthony, 354Cooper, M. Robert, 12Costerton, J. W., 447Crast, L. B., 54

Davies, M. C., 403Davis, Bernard D., 252Davis, Starkey D., 466Day, L. A., 315Del Bene, Victor E., 340Despopoulos, Agamemnon, 112Dienstag, Jules, 41Dixon, J. M. S., 333Doyle, Meade A., 310Duncan, W. Christopher, 210

Ellis, R., 242English, Arthur R., 185Ennis, Herbert L., 197, 204Eudy, W. W., 85

Farley, T. M., 274Farrar, W. Edmund, 340

Feeley, John C., 310Feingold, David S., 417Fiala, Milan, 354Fitzgerald, Robert J., 296Fleck, W., 385Fleming, W. A., 1Forland, M. F., 90Fukuda, D. S., 237

Gardner, Mildred, 148Gershon, Herman, 373Giron, David J., 78, 80Godfrey, Patricia K., 373Goldschmidt, Millicent C., 348Gordee, Elizabeth Z., 315Gordon, Ralph C., 504Gravelle, M. Joan, 470Gross, A. J., 367Guttler, Richard B., 397Guze, Lucien B., 354

Hahn, Fred E., 259Hallander, Hans O., 422Hanka, L. J., 135Hausmann, W. K., 403Holdeman, Lillian V., 451Hplder, William R., 210Holmes, K., 303Huber, F. M., 237Huppert, M., 367Hurd, Nancy, 177Hurst, A., 277

lannetta, Antoinette, 466Ikushima, H., 192Imanaka, H., 192Ishida, Nakao, 289

Jacobs, Richard L., 49Jepson, Joanne H., 174Jungstand, W., 385Jurd, L., 263

Kaye, Donald, 35, 174, 235, 381Kikuchi, Mikio, 289Killen, M., 1King, A. D., Jr., 263Kirby, J. P., 403Kirby, Susan M., 283Kirby, William M. M., 329, 504Kirchoff, Carol, 412Klainer, Albert S., 164Klastersky, Jean, 441Knight, Ralph, 381Knox, John M., 210Kobayashi, Fujio, 17, 139Kohsaka, M., 192Kominek, L. A., 123

Kruse, H., 277Kudo, Kozo, 289Kunugita, K., 192Kunz, Lawrence J., 30Kushner, D. J., 470

Lamb, John W., 323Laurell, Gunnar, 422Lee, I. P., 489Leech, Irene, 30Leitner, F., 54, 67Levison, Matthew E., 35, 174,

235, 381Lieberman, Melvin, 143Lindstrom, E. Borje, 100Lipinski, A. E., 333Lucas, G. B., 363Lukic, Aruka, 363Lynch, John E., 185

Mabe, J. A., 237, 242, 247-MacAlister, T. J., 447McCall, Charles E., 12McChatelet, Lawrence R., 12McCloskey, R. V., 90McClure, Sheena F., 1McCracken, A. W., 90Macoregor, R., 303McNeill, T. A., 1, 6Mann, Jerry M., 323Martin, D. G., 135Martin, William J., 148Medoff, Gerald, 30Mehta, B. M., 470Mercado, Carmen M., 73Mine, K., 496Minshew, Barbara H., 508Misiek, M., 54Mitsuhashi, Susumu, 17, 139Miyairi, N., 192, 496Miyoshi, T., 192Moellering, Robert C., Jr., 30Moore, W. E. C., 451Mori, S., 496Morris, A., 283

Naftchi, N. E., 392Nagarajan, R., 242Nance, Jane, 358Neft, N., 274Neu, Harold C., 41, 107Nordstrom, Kurt, 100Northrup, Robert S., 310

O'Callaghan, Cynthia H., 283Olenick, John G., 259Orfanakis, Mike G., 215

ANTIMICROB. AG. CHEMOTHER.

Palmer, Darwin L., 112Parmegiani, Raulo, 373Pascale, Andrea, 143Perkins, Robert L., 164Pindak, Frank F., 78, 80Powers, Kendall G., 49Prauser, H., 385Preston, David A., 221Price, K. E., 54, 67Pursiano, T. A., 54

Rabinovich, Sergio, 408Rael, Eppie D., 112Ray, Verne A., 185Regamey, Claude, 329, 504Reid, W., 376Reid, Y., 376Reineke, L. M., 135Retsema, James A., 185Roberts, David P., 210Rose, W. C., 489Rosenblatt, Jon E., 433Rosenblum, E. D., 508

Salkin, Ira F., 177Saslaw, Samuel, 460Schaberg, Dennis, 329Schafer, Thomas W., 143Schlamm, N. A., 512Schmidt, Jerome P., 78, 80Schoenknecht, Fritz, 433Schonfeld, C., 385Seeber, C., 385Shadomy, Smith, 412Sherris, J. C., 116Shingler, A. H., 283Simmons, Richard J., 323Smith, Charles B., 215Snyder, Robert J., 46Sparling, P. Frederick, 252Strauss, D., 385Sud, Inder Jit, 417Sun, S. H., 367Sweeney, M. J., 90Sykes, R. B., 94

Tai, Fu-Hsiang, 159Takano, N., 496Tanzer, J. M., 376Terry, E. E., 90

Tomasz, Maria, 73Tseng, Jui Teng, 22Turck, M., 303

Van Den Elzen, H. M., 22Vine, Hugh, 427

Warren, Edward, 46Washington, John A. II, 46, 148Watanabe, N., 496Weinstein, Louis, 268, 427Welty, R. E., 363Wennersten, Christine, 30Wetzel, E. R., 403Whitney, J. G., 237, 242, 247Wick, Warren E., 221Wicker, K. J., 247Wiesner, P., 303Wilcox, Howard G., 215Wilkins, T. D., 451Winshell, Elaine B., 107

Yamaguchi, Mashito, 17, 139

Zakay-Rones, Zichriya, 483

* v

AUTHOR INDEX

Sakai, H., 192

SUBJECT INDEX

VOLUME 1

Absorbable antibiotics-in fecal flora, 343Acid hydrolysis-antibiotic A16886B, 242-glycine from, 242Actinomycetes-antifungal spectra, 363Actinomycin production-by Streptomyces sp., 274-factors affecting, 274Actinomycin susceptibility-of a marine pseudomonad, 447Adenine arabinoside-effect on growth of H. saimiri, 82Amantadine-comparison with rimantadine, 408Amiceten-protein inhibition by, 2047-Aminocephalosporanic acids-structure-activity relationships, 54Aminoglycosides-tobramycin, 41, 323, 381Amoxicillin-comparative pharmacology, 504-in vitro, 358-pharmacology, 358Amphotericin B-5-FC in presence of, 476Ampicillin-against Nocardia infections, 215-combined with sulfonamides, 215-comparative pharmacology, 504Ampicillin susceptibility, 451Anaerobic bacteria-antibiotic susceptibility, 451-in vitro antimicrobial susceptibility, 148Anaerobic incubation-effect on antibiotic susceptibility, 433Animal model-for antifungal testing, 367Antagonism of activity-of tobramycin, 466Antibiotic LL-BL 136, 403Antibiotic-induced alterations-surface morphology, 164Antibiotic susceptibility-elevated atmospheric pressure, 512Antibiotic susceptibility tests-effect of anaerobic incubation, 433-reproducibility studies, 116Antibiotic synergism-against listeria, 30Anticaries agents, 376Antifungal antibiotic-cycloheximide, 177-evaluation, 367, 373Antifungal spectra

-of actinomycetes, 363Antifungal testing-animal model for, 367Antiplaque agents-preclinical evaluation, 376Antipoxvirus antibiotics, 483Antitumor antibiotic protein-neocarzinostatin, 289Antiviral agents-in EAV-infected hamsters, 143Ascorbic acid-effect on hexose monophosphate shunt, 12Aspergillus niger-antifungicide, 373Aspergillus oryzae-antifungicide, 373Atmospheric pressure-antibiotic susceptibility, 512

Bacillus megaterium-protein biosynthesis, 259Bacitracin susceptibility, 451Bacteroides fragilis-10 antimicrobial agents against, 148Biguanide chlorhexide-anticaries agent, 376BL-S 217-cephalosporanic acid, 67-properties, 67-structure, 67Biotin-new antimetabolites, 135

C1-C2 aziridine ring-mitomycin compounds lacking, 73Calcium in serum-antagonistic effect, 466Cancer patients-chemotherapeutic agents, 348Carbamate cephalosporin-from S. clavuligerus, 237, 247Carbenicillin-synergy with tobramycin, 41Carbenicillin derivative-orally active, 185Carbenicillin indanyl sodium-orally active, 185Carbenicillin susceptibility, 451Cefazolin-new cephalosporin, 221Cell wall barrier-actinomycin susceptibility, 447Cellular location-relation to Enterobacter resistance, 107Cephaloridine, 221Cephalosporanic acids-BL-S 217, 67

. .

ANTIMICROB. AG. CHEMOTHER.

-structure-activity relationships, 54Cephalosporin-cephapirin, 35-new, 303-S. aureus resistance to, 422Cephalosporin antibiotics-three new, 221Cephalosporin C acetyl esterase-formation of g-lactam antibiotic, 237Cephalosporin resistance-identification, 422Cephalosporin substrate-chromogenic, 283Cephalosporins-assay by Autoanalyzer, 100-Enterobacter resistance to, 107Cephalothin, 221-protein binding, 427-susceptibility of anaerobic bacteria, 148Cephalothin susceptibility, 451Cephanome-new cephalosporin, 221Cephapirin-evaluation, 35, 303Cephapirin sodium in serum-effect of hemodialysis, 90-effect of renal failure, 90Cephapirin sodium in urine-effect of hemodialysis, 90-effect of renal failure, 90Cephapirin therapy-neutropenia after, 174Chemoprophylaxis-of meningococcal disease, 397Chloramphenicol-susceptibility of anaerobic bacteria, 148Chloramphenicol metabolism-induction by phenobarbital, 112Chlorinated lincomycin analogues-against falciparum malaria, 49Chloroquine therapy-for Plasmodium falciparum infections, 49Clindamycin-in streptococcal infections, 460-susceptibility of anaerobic bacteria, 148Clindamycin susceptibility, 451Clinical studies-agents against B. fragilis, 148Coccidiomycosis in mice-for antifungal testing, 367Colony formation-effect of methisazone, 6Comparative pharmacology-of two ampicillins, 504Congocidine-against poxviruses, 483Cycloheximide-antifungal properties, 177Cyclophosphamide-in cancer treatment, 348-in leukemia treatment, 348Cytosine arabinoside-effect on growth of H. saimiri, 82-in leukemia treatment, 348-susceptibility of herpesviruses, 354

Dehydroascorbic acid-effect on hexose monophosphate shunt, 12Dental caries-antibiotic inhibition of, 296Dental plaques-antibacterial agents, 376Detection of ,B-lactamase-with cephalosporin, 283Diafiltration process-protein binding of penicillins, 427Diaminodiphenyl sulfone, 392Dihydro-obtusastyrene-antimicrobial properties, 263Diplococcus pneuwnoniae infection-effect of interferon inducers, 80Disc diffusion-cephalosporin resistance, 422Distamycin A-against poxviruses, 483Drug resistance-in P. aeruginosa, 22

El Tor-susceptibility to sulfamethoxazole, 310-susceptibility to trimethoprim, 310Elevated atmospheric pressure-effect on susceptibility, 512Endotoxin lethality-with L-asparaginase, 489-with cyclophosphamide, 489-with daunomycin, 489-with methotrexate, 489-with pactamycin, 489-with polyinosinic-polycytidylic acid, 489-with procarbazine, 489-with vincristine, 489Enterobacter resistance-relation to 3-lactamase activity, 107-relation to cellular location, 107-to cephalosporins, 107-to penicillins, 107Enterotoxin B-effect on S. aureus, 277Equine abortion virus-antiviral agents, 143Erythromycin-in streptococcal infections, 460-streptococci resistant to, 333-susceptibility of anaerobic bacteria, 148Erythromycin resistance-zone phenomenon, 333Escherichia coli-antibiotic-induced alterations, 164-heterozygotes, 252-polysome metabolism in, 197, 204-proflavine binding in, 470-R factor-resistant strains, 139-resistance to lividomycin, 139Ethidium bromide-effect on eukaryotic cells, 171Eukaryotic cells-ethidium bromide-treated, 171Exogenous penicillin-penicillin biosynthesis, 315

iV SUBJECTr INDEX

SUBJECr INDEX

Experimental animal model-for antifungal testing, 367

Falciparum malaria-chlorinated lincomycin analogues against, 49Fecal flora-resistance of antibiotics, 343Feed additive-thiopeptin, 192, 4965-Fluorocytosine-pharmacological studies, 476Fungal diseases-evaluation of cycloheximide against, 177Fungitoxicity-of 8-quinolinols, 373

Gentamicin-comparison with tobramycin, 381-effect of heparin, 329-susceptibility of anaerobic bacteria, 148Gentamicin/cephalothin-against oxacillin-resistant S. aureus, 441Gentamicin in serum-4-hr assay, 46Gentamicin/oxacillin-against oxacillin-resistant S. aureus, 441Gentamicin resistance-use of tobramycin, 41Gentamicin-resistant Pseudomonas-susceptibility to tobramycin, 280Glycine-from acid hydrolysis of A16886B, 242Gonorrhea-treatment with spectinomycin, 210Gram-negative bacterium-actinomycin susceptibility, 447

Hamsters-equine abortion virus-infected, 143Hemodialysis-clearance of cephapirin from blood, 90Hemopoietic cellular response-suppression by methisazone, 1Hemopoietic colony formation-effect of methisazone in vitro, 6Heparin-inhibition of gentamicin, 329Hepatic clearance-by phenobarbital, 112Herpes simplex type 2-resistance to cytosine arabinoside, 354Herpesvirus-susceptibility to cytosine arabinoside, 354Herpesvirus group-antiviral agents, 143Herpesvirus saimiri-effect of adenine arabinoside, 82-effect of cytosine arabinoside, 82-effect of rifamycin SV, 82-effect of tilorone, 82-multiplication in vitro, 823-Heterocyclic-thiomethyl antibiotics-biological properties, 221Heterozygotes-spectinomycin in, 252

Hexose monophosphate shunt-effect of ascorbic acid, 12Human neutrophils-hexose monophosphate shunt, 12

Immune response-suppression by methisazone, 1, 6Influenza A infection-rimantadine A therapy, 408Interferon-effect on D. pneumoniae infection, 80-effect on P. tularensis infection, 80Interferon inducers-effect in EAV-infected hamsters, 143Interferon induction-by tilorone hydrochloride, 78-lack of protection, 78-protection against bacteria, 80International Collaborative Study-on antibiotic susceptibility testing, 116

Kanamycin-susceptibility of anaerobic bacteria, 148Kanamycin resistance-use of tobramycin, 41

Labeled precursors-incorporation into A16886B, 247i3-Lactam antibiotics, 237, 242, 247,B-Lactam cephalosporins, 237, 242, 247,3-Lactamase activity-microiodometric determination, 94-relation to Enterobacter resistance, 107,B-Lactamases-detection, 283Lincomycin-streptococci resistant to, 333-susceptibility of anaerobic bacteria, 148Lincomycin analogues-against falciparum malaria, 49Lincomycin resistance-zone phenomenon, 333Listeria monocytogenes-antibiotic synergism against, 30Lividomycin-against P. aeruginosa, 17-enzymatic inactivation, 17-inactivation, 17, 139-R factor-resistant E. coli, 139

"Mandelic-tetrazole" derivative-"CMT," 221Meningococcal disease-minocycline chemoprophylaxis, 3976-Mercaptopurine-in cancer treatment, 348Methicillin-in streptococcal infections, 460-staphylococci resistant to, 235Methisazone-suppression of hemopoietic cellular response, 1, 6-suppression of immune response, 1Methotrexate-use in cancer patients, 348a-Methylbiotin

VOL. 1, 1972 v

ANTIMICROB. AG. CHEMOTHER.

-metabolite of biotin, 135a-Methyldethiobiotin-metabolite of biotin, 135Microiodometric method-adapted for penicillin, 100-for ,B-lactamase assay, 94Minocycline-for meningococcal disease, 397Mitomycin C-chemical derivatives, 73Mitomycin-related compounds-lacking C1-C2 aziridine ring, 73MM virus infection-lack of protection by interferon, 78Monkeys-streptococcal infections in, 460Morphological alterations-antibiotic-induced, 164Mycobacterium tuberculosis-inhibition of growth, 392Myrothecium verrucaria-antifungicide, 373

Nafacillin-protein binding, 427Natural phenols-antimicrobial properties, 263Nebramycin factor 6-tobramycin, 41, 323, 412Neisseria meningitidis-minocycline activity against, 397Neocarzinostatin-biogenesis, 289Neutropenia-after cephapirin therapy, 174Neutrophils-hexose monophosphate shunt, 12Nisin-effect on S. lactis, 277Nocardia asteroides-antibiotic therapy against, 215Nonabsorbable antibiotics-in fecal flora, 343Novobiocin-biosynthesis by S. niveus, 123Novobiocin synthesis-proposed pathway, 123

Obligate parasitism-of trachoma agent, 171Obtusastyrene-antimicrobial properties, 263Oral prophylaxis-in protected environment, 343Owl monkeys-falciparum malaria in, 49Oxacillin-protein binding, 427Oxacillin-resistant staphylococci-antibiotic susceptibility of, 441

Pasteurella tularensis infection-effect of exogenous L-cell interferon, 80-effect of interferon inducers, 80

Penicillin biosynthesis-exogenous penicillin, 315Penicillin fermentation-effect of phenoxymethylpenicillin, 315Penicillin G-for gonorrhea treatment, 210-susceptibility of anaerobic bacteria, 148Penicillin susceptibility, 451Penicillinases-assay by Autoanalyzer, 100Penicillins--assay by Autoanalyzer, 100-Enterobacter resistance to, 107Permeability barriers-relation to proflavine binding, 470Periodontal disease-agents against, 376Phenobarbital-induction of chloramphenicol metabolism by, 112Phenoxymethylpenicillin-effect on penicillin fermentation, 315Plasmodium Jalciparum infections-chloroquine therapy, 49Polymorphonuclear leukocytes-hexose monophosphate shunt, 12Polymyxin B-P. mirabilis resistance to, 417Polysome metabolism-effect of amicetin on, 204-in E. coli, 197, 204-in vivo, 197, 204Polysome stability-antibiotic effect on, 197, 204Poxvirus-antibiotics against, 483Primaquine-mode of action, 259Proflavine binding-in E. coli, 470-relation to permeability, 470Protected environment-oral antibiotic prophylaxis in, 343Protein binding of penicillins-reversibility, 427Protein biosynthesis-in B. megaterium, 259-inhibition by primaquine, 259Protein synthesis-antibiotic-induced alterations in, 164-inhibition by amicetin, 204-inhibition by antibiotics, 197, 204Proteus mirabilis-resistance to polymyxin B, 417Proteus species-carbenicillin against, 185Pseudomonas-gentamicin-resistant, 280-in leukemic patients, 348-tobramycin against, 466Pseudomonas aeruginosa-antibiotic-induced alterations, 164-carbenicillin against, 185-lividomycin against, 17-toxicity of vincristine with, 489

Vi SUBJECT INDEX

SUBJECT INDEX

-transferable drug resistance, 22Pyelonephritis-P. mirabilis-induced, 85Pyocin B39-chemical properties, 159-physical properties, 159-purification, 159

8-Quinolinols-antifungal activity, 373Quinolyl aryl ethers-antimicrobial activity, 392Quinolyl aryl sulfides-antimicrobial activity, 392Quinolyl aryl sulfones-antimicrobial activity, 392

R factor-resistant Escherichia coli-activity of lividomycin, 139Renal lysozyme-elevation after P. mirabilis infection, 85-elevation by ampicillin, 85-elevation by kanamycin sulfate, 85-elevation by nitrofurantoin, 85Reproducibility of antibiotic susceptibility tests-with different media, 116Resistance to drugs-in P. aeruginosa, 22Rifampin-susceptibility of anaerobic bacteria, 148Rifamycin SV-effect on growth of H. saimiri, 82Rimantadine-for influenza A therapy, 408

Salmonella typhosa endotoxin-toxicity for mice, 489Semisynthetic penicillin-amoxicillin, 358Serum sulfonamide concentration-two bioassay techniques, 268Sheep erythrocytes-suppressive activity of methisazone, 1Spectinomycin-comparison with streptomycin, 252Spectinomycin hydrochloride-for gonorrhea treatment, 210Staphylococci-methicillin-resistant, 235Staphylococcus aureus-antibiotic-induced alterations, 164-antibiotic susceptibility, 512-cephasporin-resistant strains, 422-effect of enterotoxin B, 277-methicillin-resistant strains, 235-oxacillin-resistant strains, 441Staphylococcus epidermidis-tetracycline resistance in, 508Streptococcal infections-in monkeys, 460Streptococci-group A beta-hemolytic, 333Streptococcus lactis-inhibition by nisin, 277

Streptococcus mutans-from carious rats, 296Streptococcus pyogenles-antibiotic susceptibility, 512-resistance to erythromycin, 333-resistance to lincomycin, 333Streptomyces antibioticus-growth in chemically defined medium, 274Streptomyces carzinostatin-neocarzinostatin from, 289Streptomyces clavuligerus-cephalosporin from, 237, 242, 247Streptomyces diastatochromogenes-trypanomycin from, 385Streptomyces niveus-biosynthesis of novobiocin by, 123Streptomyces species-actinomycin production by, 274Streptomyces spectabilis-antibiotic from, 210Streptomyces iateyamensis-thiopeptin from, 192, 496Streptomyces tenebrarius-tobramycin from, 41Streptomycin-bactericidal action, 252-comparison with spectinomycin, 252Streptothricin-type antibiotics-analytical method, 403Structure-activity relationships-among cephalosporanic acids, 54Sulfamethoxazole-susceptibility of V. cholerae, 310Sulfonamide-concentration in serum, 268-oral administration, 268Sulfonamide concentration-chemical determination, 268Sulfonamides-against Nocardia infections, 215-combined with ampicillin, 215Susceptibility testing-of anaerobic bacteria, 451Synergistic action-against L. monocytogenes, 30

Technicon Autoanalyzer system-for penicillin assay, 100Tetracycline-susceptibility of anaerobic bacteria, 148Tetracycline resistance-in S. epidermidis, 508-transduction of, 508Tetracycline susceptibility, 451Thiopeptin-chemical studies, 192-feed additive, 192-microbiological studies, 192-new feed additive, 496Thiopeptin A antibiotics-comparison with thiopeptin B, 192Tilorone-effect on growth of H. saimiri, 82Tilorone hydrochloride

*iiVOL. 1, 1972

viii SUBJECT INDEX

-induction of interferon by, 78Tobacco-actinomycetes from, 363Tobramycin-against Pseudomonas, 466-evaluation, 412-in vitro evaluation, 381-in vitro studies, 41, 412-microbiological assay, 323-susceptibility of Pseudomonas, 280-synergy with carbenicillin, 41Tobramycin activity-effect of calcium in serum, 466Tobramycin assay-agar-plate, 323-iron and sodium ions, 323Toxicity of vincristine-with P. aeruginosa, 489-with S. typhosa endotoxin, 489Trachoma agent-obligate parasitism, 171Trichoderma viride-antifungicide, 373

ANTIMICROB. AG. CHEMOTHER.

Trichophyton mentagrophytes-antifungicide, 373Trimethoprim-susceptibility of V. cholerae, 310Trypanomycin-characterization, 385-fermentation, 385-isolation, 385-screening, 385

Urinary tract antibiotics-effect on renal lysozyme levels, 85

Venereal disease-spectinomycin hydrochloride, 210Vibrio cholerae, classical strains-susceptibility to sulfamethoxazole, 310-susceptibility to trimethoprim, 310Vincristine-enhanced toxicity, 489Virus inhibitory titers-method to measure, 354